Holen Sie sich die Stockscreener-App
55.01
3.69%
-2.11
Vorhandelsmarkt:
55.75
0.74
+1.35%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations - Yahoo Finance
TGTX Maintained by HC Wainwright & Co. -- Price Target Raised to $77 - GuruFocus
TG Therapeutics Initiates Phase 2 Trial of Briumvi, Expanding Pipeline PotentialGuidance Upgrade Report - DonanımHaber
(TGTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss - Stocktwits
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial - Insider Monkey
TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News - Yahoo Finance
2 Fast-Growing Pharmaceutical Stocks to Buy Now - The Motley Fool
Can TG Therapeutics' (TGTX) Schizophrenia Trial Meaningfully Redefine BRIUMVI’s Role Beyond Multiple Sclerosis? - Yahoo Finance
Is TG Therapeutics (TGTX) Fully Valued Following Its Schizophrenia Trial Update? - Yahoo Finance
ETFs Investing in TG Therapeutics, Inc. Stocks - TradingView
Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX) - The Globe and Mail
5 Best Performing American Stocks in June 2026 - Insider Monkey
TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch - Yahoo Finance
TGTX Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
TG Therapeutics stock hits 52-week high at 57.4 USD By Investing.com - Investing.com South Africa
TG Therapeutics stock hits 52-week high at 57.4 USD - Investing.com
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia - The Globe and Mail
TG Therapeutics, Inc. Stock 12‑Month Price Target Raised to $52.14, Implies 6% Downside - TradingView
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $70 - Moomoo
TGTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $70 - GuruFocus
TG Therapeutics begins schizophrenia Phase 2 trial - grafa.com
TG Therapeutics begins trial of Briumvi for schizophrenia By Investing.com - Investing.com Australia
TG Therapeutics begins trial of Briumvi for schizophrenia - Investing.com
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia - The Manila Times
TG Therapeutics Initiates Phase 2 Trial of BRIUMVI in Treatment-Resistant Schizophrenia - Quiver Quantitative
TG Therapeutics tests BRIUMVI in 60 schizophrenia patients - Stock Titan
TG Therapeutics, Inc. (TGTX) Investor Outlook: Navigating Growth with High Potential in Biotech - DirectorsTalk Interviews
TG Therapeutics Inc. (TGTX) Q1 2026 Earnings: EPS Misses Estimates Amid Revenue UncertaintyReturn On Equity - dars.gov.et
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance - marketscreener.com
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2? - Yahoo Finance
TGTXTG Therapeutics Inc Dividends - Finviz
TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength - ChartMill
TG THERAPEUTICS INC (TGTX) Stock Chart - ChartMill
Price to sales forward of TG Therapeutics, Inc. – NASDAQ:TGTX - TradingView
Price to earnings forward of TG Therapeutics, Inc. – MIL:1TGTX - TradingView
Does TG Therapeutics (NASDAQ:TGTX) Deserve A Spot On Your Watchlist? - Moomoo
TG Therapeutics Surged 88%: Time To Be More Careful (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha
Responsive Playbooks and the TGTX Inflection - Stock Traders Daily
TGTX stock continues rally for 8 straight sessions on new BRIUMVI clinical data - MSN
NKB2 Forecast — Price Target — Prediction for 2027 - TradingView
TG Therapeutics (TGTX) soars 7.5%: Is further upside left in the stock? - MSN
TG Therapeutics Board Authorizes New $100M Share Repurchase Program - MSN
Price to earnings forward of TG Therapeutics, Inc. – NASDAQ:TGTX - TradingView
Enterprise value to EBITDA forward of TG Therapeutics, Inc. – FWB:NKB2 - TradingView
Price to book forward of TG Therapeutics, Inc. – FWB:NKB2 - TradingView
Enterprise value to EBIT forward of TG Therapeutics, Inc. – NASDAQ:TGTX - TradingView
Enterprise value to EBIT forward of TG Therapeutics, Inc. – LSX:A1JXW7 - TradingView
Price to sales forward of TG Therapeutics, Inc. – FWB:NKB2 - TradingView
Enterprise value to revenue forward of TG Therapeutics, Inc. – NASDAQ:TGTX - TradingView
TG Therapeutics, Inc. Actuals & Estimates (NASDAQ:TGTX) - TradingView
TG Therapeutics, Inc. Actuals & Estimates (MIL:1TGTX) - TradingView
Price to earnings forward of TG Therapeutics, Inc. – LSX:A1JXW7 - TradingView
Price to sales forward of TG Therapeutics, Inc. – LSX:A1JXW7 - TradingView
TGTX Forecast — Price Target — Prediction for 2027 - TradingView
TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data - Stocktwits
TG Therapeutics Inc (TGTX) Institutional Confidence - TradingKey
TG Therapeutics Stock 10-Day Winning Spree: Stock Climbs 35% - Trefis
5.60%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):